Streetbeat News

Stock Prices

DEO

Sean 'Diddy' Combs and Diageo plc (NYSE:DEO) have ended their partnership on Cîroc vodka and DeLeón tequila, with Diageo now holding complete ownership of DeLeón. The split follows a legal dispute where Combs sued Diageo for neglecting DeLeón and alleged racial discrimination. The financial details of the settlement are undisclosed, but Combs has dropped all allegations. Diageo had cited contract breaches by Combs as the reason for the partnership's end. DEO shares closed lower by 0.96% at $141.75.

Portfolio Pulse from Shivani Kumaresan

January 17, 2024 | 12:33 pm

SCHW

Charles Schwab reported Q4 2023 adjusted EPS of $0.68, surpassing the $0.64 estimate, but sales of $4.46B fell short of the $4.48B estimate, marking an 18.88% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:31 pm

MAT

Morgan Stanley analyst Megan Alexander downgraded Mattel (NASDAQ:MAT) from Overweight to Equal-Weight and set a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:25 pm

TSP

Trading for TSP has resumed at 7:25 AM ET after a temporary halt. The halt status update included news and resumption times for the stock.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:25 pm

MS

Keefe, Bruyette & Woods analyst David Konrad downgraded Morgan Stanley (NYSE:MS) from Outperform to Market Perform and reduced the price target from $102 to $91.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:23 pm

CART

Wolfe Research analyst Deepak Mathivanan has upgraded Maplebear (NASDAQ:CART) from Peer Perform to Outperform and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:21 pm

BLUE

CRSP

VRTX

The FDA approved CRISPR Therapeutics AG's and Vertex Pharmaceutical Incorporated's Casgevy for transfusion-dependent beta-thalassemia in patients 12 years and older, ahead of its PDUFA date. Vertex is setting up treatment centers across the U.S. for Casgevy, which is also approved for sickle cell disease. Analysts predict a 'slow and steady launch' with peak sales of about $400 million. Bluebird Bio Inc's Lyfgenia was also approved for sickle cell disease. Vertex's stock closed at $437.49, and CRISPR's at $63.43.

Portfolio Pulse from Vandana Singh

January 17, 2024 | 12:15 pm

MARA

BTIG analyst Gregory Lewis upgraded Marathon Digital Holdings (NASDAQ:MARA) from Neutral to Buy and set a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:13 pm

ETHUSD

SOL

A trader capitalized on Elon Musk's Twitter bio change to 'Chief Troll Officer' by purchasing TROLL tokens, which surged in value, turning $300 into $1.03 million in ten days. The event highlights how traders respond to Musk's social media activities, with similar occurrences in the past involving tokens like GROK and WIF.

Portfolio Pulse from Mehab Qureshi

January 17, 2024 | 12:07 pm

FUTU

JP Morgan analyst Katherine Lei has upgraded Futu Holdings (NASDAQ:FUTU) from Neutral to Overweight and set a price target of $64.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:06 pm